CD169 Expression in Lymph Nodes is Associated with Increased Infiltration of CD8⁺ T Cells in Tumors: A Systematic Review and Meta-Analysis

Table 2

The number of patients in different CD169 and CD8 expression.

Study		Low CD169 (N)	High CD169 (N)	CD169 (IT vs. NT)	HR for OS in high CD169 (95% CI)
Kumamoto et al. [19]	Low CD8	90/147	57/147	NR	Total GC: 0.41 (0.25–0.69)
	High CD8	45/147	102/147		Advanced GC: 0.38 (0.22–0.66)
Zhang et al. [20]	Low CD8	31/38	7/38	FACS (%); 45 ± 10.2; vs.; 87.5 ± 5.6	0.50 (0.3–0.70)
	High CD8	2/9	7/9
Ohnishi et al. [14]	Low CD8	30/42	12/42	NR	1.29 (0.72–2.39)
	High CD8	15/41	26/41
Takeya et al. [21]	Low CD8	PT+: 22/29; PT-: 26/48	PT+: 9/20; PT-: 29/43	NR	0.662 (0.297–1.371)
	High CD8	PT+: 7/29; PT-: 22/48	PT+: 11/20; PT-: 14/43
Li et al. [22]	Low CD8	HCC: 16/31; GC: 11/24	HCC: 15/31; GC: 13/24	IHC (%); HCC; 30.4 ± 8.5; vs.; 60.9 ± 14.3	0.436 (0.27–0.703)
	High CD8	HCC: 1/8; GC: 8/16	HCC: 7/8; GC: 8/16	GC; 46.3 ± 8; vs.; 88.4 ± 3.2	0.587 (0.354–0.974)
Asano et al. [23]	Low CD8	19/25	6/25	NR	0.13 (0.01–0.76)
	High CD8	7/19	12/19
Ohnishi et al. [15]	Low CD8	20/36	16/36	NR	0.23 (0.06–0.69)
	High CD8	17/39	22/39
Saito et al. [16]	Low CD8	17/33	16/33	NR	0.38 (0.21–0.70)
	High CD8	10/20	10/20
Shiota et al. [24]	Low CD8	13/27	14/27	NR	0.57 (0.11–3.64)
	High CD8	11/22	11/22
Kawaguchi et al. [25]	Low CD8	17/31	14/31	NR	3.009 (1.374–6.692)
	High CD8	11/58	47/58

N: number; OS: overall survival; HR: hazard ratio; GC: gastric cancer; HCC: hepatocellular carcinoma; IT: intro-tumor; NT: nontumor; IHC: immunohistochemistry; FACS: flow cytometry; PT: pretreatment; NR: not reported.